Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cardio Diagnostics Holdings Inc
NASDAQ:CDIO
|
US |
|
GreenTree Hospitality Group Ltd
NYSE:GHG
|
CN |
|
K
|
Kotra Industries Bhd
KLSE:KOTRA
|
MY |
|
Nemetschek SE
XETRA:NEM
|
DE |
|
Radaan Media Works India Ltd
NSE:RADAAN
|
IN |
|
Assa Abloy AB
OTC:ASAZY
|
SE |
|
Heubach Colorants India Ltd
NSE:HEUBACHIND
|
IN |
|
Sinocelltech Group Ltd
SSE:688520
|
CN |
|
Ulima Nitra Tbk PT
IDX:UNIQ
|
ID |
|
Base Inc
TSE:4477
|
JP |
Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings Inc is a US-based company operating in industry. The company is headquartered in Dover, Delaware. The company went IPO on 2021-11-23. Cardio Diagnostics Holdings, Inc., formerly Mana Capital Acquisition Corp., is a biotechnology company that helps in cardiovascular disease prevention and early detection accessible. The firm is engaged in the development and commercialization of artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The company enables prevention, early detection, and assists in the treatment of cardiovascular disease. The firm's Epi+Gen CHD is a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. Its Epi+Gen CHD test is categorized as a laboratory-developed test (LDT), which does not require premarket authorization or other Food and Drug Administration (FDA) clearance or approval. The company serves a range of patients, clinicians, hospitals/health systems, employers, and payors.
Cardio Diagnostics Holdings Inc is a US-based company operating in industry. The company is headquartered in Dover, Delaware. The company went IPO on 2021-11-23. Cardio Diagnostics Holdings, Inc., formerly Mana Capital Acquisition Corp., is a biotechnology company that helps in cardiovascular disease prevention and early detection accessible. The firm is engaged in the development and commercialization of artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. The company enables prevention, early detection, and assists in the treatment of cardiovascular disease. The firm's Epi+Gen CHD is a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. Its Epi+Gen CHD test is categorized as a laboratory-developed test (LDT), which does not require premarket authorization or other Food and Drug Administration (FDA) clearance or approval. The company serves a range of patients, clinicians, hospitals/health systems, employers, and payors.
